To the full analysis
Quest Diagnostics stock: growth
DGXQuest Diagnostics reported $11.04B in revenue for fiscal 2025, up 11.8% on the prior year, up 3.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3%
per year from 2006 to 2025, per share 6.2%
Earnings (Annual rate)
2.8%
per year from 2006 to 2025, per share 5.9%
Free cash flow (Annual rate)
3.1%
per year from 2006 to 2025, per share 6.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 3.2% | 3.9% | 3.0% |
| Revenue per share | 7.1% | 6.7% | 6.2% |
| Earnings | −7.1% | 3.4% | 2.8% |
| Earnings per share | −3.6% | 6.1% | 5.9% |
| Free cash flow | −3.1% | 9.5% | 3.1% |
| Free cash flow per share | 0.7% | 12.4% | 6.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $6.27B | $586.42M | $758.47M |
| 2007 | $6.7B | $339.94M | $707.82M |
| 2008 | $7.25B | $581.5M | $850.4M |
| 2009 | $7.46B | $729.1M | $830.5M |
| 2010 | $7.37B | $720.9M | $912.6M |
| 2011 | $7.51B | $470.6M | $734M |
| 2012 | $7.38B | $555.7M | $1B |
| 2013 | $7.15B | $849M | $421M |
| 2014 | $7.44B | $556M | $630M |
| 2015 | $7.49B | $709M | $547M |
| 2016 | $7.52B | $645M | $776M |
| 2017 | $7.71B | $772M | $923M |
| 2018 | $7.53B | $736M | $817M |
| 2019 | $7.73B | $858M | $843M |
| 2020 | $9.44B | $1.43B | $1.59B |
| 2021 | $10.79B | $2B | $1.83B |
| 2022 | $9.88B | $946M | $1.31B |
| 2023 | $9.25B | $854M | $864M |
| 2024 | $9.87B | $871M | $909M |
| 2025 | $11.04B | $992M | $1.36B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Apr 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.